|Marta Woźniak, Roman Nowicki|
The treatment of psoriasis, which is in fact an immunological disease, continues to be a major therapeutical problem. The patients affected with that chronic disease have been waiting for better and more effective treatment. The introduction of new biological drugs may bring a breakthrough in psoriasis treatment. Four new biologicals have been reported: efalizumab, alefacept, etanercept and infliximab, which for a short time have been used in psoriasis treatment. The results show that the advanced and chronic symptoms disappear completely, and the biologicals are characterised by high efficiency in the treatment of the resistant and the advanced forms of psoriasis. A review of literature on the new biological drugs is included.
keywords: łuszczyca, efalizumab, alefacept, infliksimab, etanercept, psoriasis, efalizumab, alefacept, infliximab, etanercept
pages: from 29 to 34
|estimated time of download (127 kB)|